 |
|
|
| |
First-Line Raltegravir (RAL) + Darunavir/Ritonavir (DRV/r) is Non-inferior to Tenofovir/Emtricitabine (TDF/FTC) + DRV/r: The NEAT 001/ANRS 143 Randomised Trial
|
| |
| |
Reported by Jules Levin
CROI 2014 March 3-6 Boston, MA
Franois Raffi1, Abdel G Babiker2, Laura Richert3, Jean-Michel Molina4,
Elizabeth C George2, Andrea Antinori5, Jose Arribas6, Stefano Vella7,
Genevieve Chne3, Anton L Pozniak8, and the NEAT001/ANRS143 Study Group
1University Hospital, Nantes, France; 2MRC Clinical Trials Unit at UCL, London, UK ; 3INSERM U897, Bordeaux, France; 4St Louis Hospital and University of Paris 7, France; 5INMI L Spallanzani, Rome, Italy; 6Hospital La Paz, IdiPAZ, Madrid, Spain; 7Istituto Superiore di Sanita, Rome, Italy ; 8Chelsea and Westminster Hospital, NHS Foundation Trust, London, UK
CROI webcast:
http://www.croiwebcasts.org/console/player/22172?mediaType=slideVideo&
|
| |
|
|
|
|
|
